Answers are grounded in this paper and cite their sources.
The history of prevention of mother-to-child transmission (PMTCT) of HIV in resource-constrained settings has been defined by addressing and overcoming a series of successive dilemmas over the last 15 years. These scientific and operational dilemmas have focused on the optimal HIV testing and counselling strategies (from an individualized opt-in approach to routine, provider-initiated rapid testing and counselling with same-day results) [1–3], infant feeding guidance (from no breastfeeding or short duration breastfeeding with rapid weaning to breastfeeding at least through 12 months in the presence of appropriate antiretroviral coverage) [4–6] and the most appropriate antiretroviral interventions (from short-course zidovudine or single-dose nevirapine (NVP) to successively longer and more effective antiretrovirals covering the full MTCT risk period of pregnancy, labour and delivery, and breastfeeding) [7,8]. Changes in international recommendations every 2–3 years have reflected the rapid evolution of evidence and the increasing capacity and expectations to deliver more effective interventions, but have posed continued new challenges in the field. With the new 2013 WHO consolidated guidelines [9] recommending that all HIV-positive pregnant and breastfeeding women start triple antiretrovirals, and that all women either continue lifelong treatment (’Option B+’, a universal treatment approach) or that only those meeting other eligibility criteria (i.e. immunologic, clinical or serodiscordance) continue therapy beyond the MTCT risk period (‘Option B’), attention is focusing on the early Malawi experience, wherein Option B+ was first conceived and initiated. The underlying rationale for Option B+ has been clearly articulated [9–12]. Key benefits include assuring that all ‘ART-eligible’ pregnant women receive triple antiretrovirals for their own health as well as to prevent MTCT, preventing MTCT in future pregnancies, avoiding the risks of starting and stopping antiretrovirals, potential health benefits of early initiation of ART and a major simplification of programmes, algorithms, drug regimen (a once-daily fixed-dose combination of tenofovir/lamivudine (or emtricitabine/efavirenz) and messages. At the same time, there continues to be some controversy over the Option B+ approach [13]. Moreover, WHO has highlighted key operational issues and research questions that need to be addressed, including the acceptability of life-long antiretroviral treatment in women not otherwise eligible for treatment, and adherence and retention on the antiretrovirals, both throughout the MTCT risk period (this applies to both Options B and B+) and long-term retention on chronic ART. The Malawi programme has pioneered a nation-wide quarterly review of aggregate data and has been remarkably transparent in sharing early results of its Option B+ programme [14,15]. The more detailed analysis of patient-level data reported in this issue of AIDS by Tenthani [16] sheds additional light on the early experience of acceptability and retention in the programme. The underlying rationale of the Malawi ‘Option B+’ programme was to provide a highly effective antiretroviral therapy (ART) intervention during pregnancy and the prolonged breastfeeding period (typically 24 months in Malawi), in the setting of limited CD4+ cell count testing and high fertility. The early results have been very impressive; this strategy rapidly led to a six-fold increase in the number of pregnant or breastfeeding HIV-infected women starting ART [14] and PMTCT antiretroviral coverage (antiretroviral initiation) of greater than 60% nationwide. However, the critical issue is acceptability of this universal treatment approach, assessed here by early retention in care. The authors analyse a very large national dataset of individual data, compare sites with and without an electronic medical records (EMRs) database, compare retention between pregnant and breastfeeding women starting B+ with nonpregnant women initiating treatment in ART clinics and make an important distinction between those who immediately drop out (no follow-up at all after testing HIV-positive) and those who initiate ART and are subsequently lost to follow-up (LTFU). So what is the early experience with retention in Malawi and what should we conclude? First, up to 20% of women testing HIV-positive in antenatal or postpartum clinics dropped out apparently before initiating ART. The data suggest that women who were not given ART on the same day as their HIV-positive test did better. This highlights the need for programmes to carefully assess the quality of ART counselling and support provided at initiation, consider that not all women are ready to start ART on the same day as testing, and to consider peer support and defaulter tracking from day one. Second, of those who actually start ART (and return for at least one follow-up visit), the LTFU rate at 6 months was 17% and had wide variation among sites, including higher LTFU at larger, urban clinics and at clinics with EMRs. This suggests problems with counselling and support in large clinic settings, and, among some women, either a lack of understanding of the ‘B+ message’ of lifelong treatment or a lack of acceptability. Paradoxically, LTFU was higher in settings with EMRs. The authors point out some methodologic differences in their definitions of LTFU in the two settings, but the finding raises the question of whether the EMR is only being used to document visits and follow-up, or if it is also being used to support efforts to track those who missed an appointment. The problem surely is not the EMR, but how the EMR can be used effectively to limit LTFU. Third, although there are a number of potential confounders, the data suggest that women in the PMTCT B+ programme had higher rates of LTFU than nonpregnant eligible women in the ART treatment clinics. The higher retention rates among women starting treatment in ART clinic are likely explained by better adherence counselling and more time to prepare to start ART, the motivation for treatment that comes with symptomatic disease, and the longer experience and training of staff in the ART clinics. The comparison can point to ways to improve the provision of ART in the PMTCT B+ programme, especially as PMTCT and ART programmes converge, but the differences should not be over-interpreted, as the clinics and contexts are likely quite different. Perhaps the most troubling part of this report is the observation that 20% of HIV-positive women did not actually start their ART, although most were provided with ART at their initial visit. Although most ART programmes include a substantial phase of pre-ART adherence and readiness counselling, in the PMTCT setting, there is a time urgency to start antiretrovirals and the model has been to do an HIV test and initiate antiretrovirals, most typically zidovudine, at the first antenatal visit. More work is needed, with substantial community and civil society input, to develop the appropriate messages of support for this radically condensed, life-changing event. Context-appropriate ART initiation, adherence and retention counselling and support are needed in PMTCT programmes, particularly in those moving to B+. We should have a high bar for our expectations for retention in Option B+ programmes, but we should also keep in mind that adherence and retention historically in PMTCT have been low in many programmes and with many different antiretroviral interventions, including the single-dose NVP [17], short-course antiretroviral interventions and the previously recommended Option A approach [18]. Furthermore, high LTFU, failure to complete PMTCT antiretroviral interventions, especially during breastfeeding, and poor linkages to chronic antiretroviral care have been the Achilles heel of PMTCT programmes. Indeed, in Malawi, the previous programme provided single-dose NVP and no antiretroviral protection or follow-up during breastfeeding, and the innovative site supervision approach that now provides follow-up data was only introduced with the transition to B+. Malawi has rightly received recognition for its bold public health approach with B+. It should be further congratulated for its transparency and critical presentation of early data. Their reports provide clear evidence that the national B+ programme is up and running and has achieved remarkable scale-up in its initial phase. But this report also suggests substantial challenges, particularly at ART initiation and early postpartum retention. We await further reports from Malawi on how they have used these data to improve their programme, as well as data on longer term retention (at least through the end of the MTCT risk period) and other key maternal and child health outcomes such as vertical transmission rates and HIV-free survival. We also encourage the many other countries beginning B+ to institute similar systematic and ongoing reviews of retention in their programmes. With the 2013 WHO guidelines, and the global movement towards Option B and B+ for PMTCT programmes, we have moved from the antiretroviral dilemma of which antiretroviral regimen to use to the challenge of how to effectively implement triple antiretrovirals to prevent vertical transmission and promote the long-term health of the mother and her child. Acknowledgements E.J.A. was a cochair, R.B. was a core group member and N.S. was the WHO facilitator of the Maternal and Child Health section of the WHO 2013 consolidated antiretroviral guidelines development group. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Shaffer et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: